NASDAQHealth CareMedical DevicesSnapshot 2026-07-23
Reading STIM? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. The company is currently navigating through a volatile management phase while aiming for revenue growth and cost optimization.
The market seems to have priced in a justified valuation, with STIM appearing cheap compared to its peers. However, there is a notable expectations gap, indicating that the market may not fully anticipate the potential challenges ahead.
Management is on track to achieve its revenue goals for 2026, but gross margins are slightly below target. The recent financial performance has been neutral, with a low probability of missing expectations, although the company operates in a smaller-cap space with higher risks.
The thesis hinges on the performance of sector bellwethers like ABT, SYK, and MDT. Positive earnings from these companies could support STIM, while any negative guidance could lead to a decline in momentum.
Over the next 1 to 3 years, STIM's trajectory will depend on its ability to navigate management changes and sector performance. Not investment advice.
The most important moves since the prior daily snapshot.
Company momentum fell by 17.2 points (from 44.0 to 26.8).
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: This report will show details about revenue and margins. It will also show overall performance.
Confirms one read:Earnings report shows revenue and margins meeting or exceeding targets.
Confirms the other:The earnings report shows big misses on revenue and margins.
Why it matters: This growth shows that Neuronetics can meet its yearly revenue goal. It shows demand for their NeuroStar therapy.
Confirms:Q2 2026 revenue growth reported at 5% or higher compared to Q1 2026.
Disproves:Q2 2026 revenue growth reported below 5% compared to Q1 2026.
Why it matters: Good cost management can make finances stronger. It also helps meet growth goals.
Confirms:The company announced it has reduced its workforce. This fits with plans to cut costs.
Disproves:There has been no progress on reducing the workforce.
Why it matters: Keeping this margin is important for making money. It shows how well costs are managed.
Confirms:Gross margin reported at 47% or higher for Q2 2026.
Disproves:Gross margin reported below 47% for Q2 2026.
Why it matters: Policy changes that expand access can lead to increased patient volume and revenue. This is a strategic growth initiative.
Confirms:More health plans are adding coverage for NeuroStar therapy. This goes beyond the current 34.8 million covered lives.
Disproves:No new health plans are adding coverage for NeuroStar therapy.
